Jan. 22 Quick Takes: CDC updates advice on COVID vaccine dosing; plus more vaccines for COVAX and RCC approval for Opdivo-Cabometyx and more 

CDC said the second dose of COVID-19 vaccines from  Moderna Inc. (NASDAQ:MRNA) and partners  BioNTech SE (NASDAQ:BNTX) and  Pfizer Inc. (NYSE:PFE) can be administered up to six weeks after the first dose. The prior recommendation had been three weeks for Comirnaty from Pfizer and BioNTech and four weeks for the Moderna product, according to CDC. The agency also noted that the mRNA vaccines are not interchangeable with each other or with other COVID-19 vaccines.

Separately, BioNTech and Pfizer will supply COVAX with up to 40 million doses this year of Comirnaty at a not-for-profit price. The first deliveries are due this quarter to COVAX, a global partnership that aims to make it possible for at least 20% of the population of low- and middle-income countries to have access to COVID-19 vaccines...